SCHEMBL26773301

SCHEMBL26773301

NC(=O)c1nn(-c2c(Cl)cccc2Cl)cc1Nc1ccc(C(=O)N2CCN(C3CC3)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNT1 O60563 1/20 0.42
▸ CDK4 P11802 1/20 0.42
▸ CCND1 P24385 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ CDK11A Q9UQ88 1/20 0.42
▸ JAK1 P23458 3/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ TYK2 P29597 1/20 0.42
▸ JAK3 P52333 1/20 0.42
▸ L3MBTL3 Q96JM7 8/20 0.41
▸ L3MBTL1 Q9Y468 6/20 0.41
▸ BTK Q06187 2/20 0.41
▸ MBTD1 Q05BQ5 5/20 0.40
▸ TP53BP1 Q12888 2/20 0.40
▸ L3MBTL4 Q8NA19 2/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM4 P08173 1/20 0.40
▸ CHRM5 P08912 1/20 0.40
▸ CHRM1 P11229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26773320 0.89 MAPT (0.47) CCNT1CDK4CCND1CDK9CDK6
SCHEMBL26773315 0.89 TYK2 (0.45) CCNT1CDK4CCND1CDK9CDK6
SCHEMBL26773485 0.89 HRH3 (0.49) L3MBTL3L3MBTL1BTKMBTD1TP53BP1
SCHEMBL26773486 0.89 HRH3 (0.49) L3MBTL3L3MBTL1BTKMBTD1TP53BP1
SCHEMBL26773395 0.89 HRH3 (0.49) L3MBTL3L3MBTL1BTKMBTD1TP53BP1
SCHEMBL26773188 0.88 CCNT1 (0.52) CCNT1CDK4CCND1CDK9CDK6
SCHEMBL26773525 0.88 HRH3 (0.42) JAK2TYK2L3MBTL3L3MBTL1HRH3
SCHEMBL26773557 0.88 HRH3 (0.45) L3MBTL3L3MBTL1HRH3
SCHEMBL26777206 0.88 HPGD (0.47) CCNT1CDK4CCND1CDK9CDK6
SCHEMBL26773322 0.88 HPGD (0.47) CCNT1CDK4CCND1CDK9CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192464-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Origenis GmbH (DE) 2023-06-14 — — EP claimed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 CCNT1 3299/4885CDK4 698/4885CCND1 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback